Boston Scientific
(NYSE: BSX)
today announced a catheter development and commercialization deal with Siemens Healthineers.
The deal centers around the workflow development and commercialization of Siemens Healthineers’ next-generation, investigational AcuNav 4D intracardiac echocardiography (ICE) catheter. AcuNav 4D ICE technology is designed to enable device guidance with optimal imaging quality. It helps to avoid the need to cross the imaging catheter into the left atrium. This avoids potential complications that can arise from catheter usage in this area.
Under the agreement, Boston Scientific becomes the exclusive distributor of the AcuNav 4D ICE catheter in the U.S. and Japan.
Boston Scientific says that, once commercially available, this catheter could offer physicians an imaging option for procedures using its Watchman left atrial appendage closure (LAAC) device and Farapulse pulsed field ablation (PFA) platform. Those cases include LAAC procedures, concomitant FaraWatch procedures that use Watchman and Farapulse, and other structural heart procedures.
The company says most Watchman cases use transesophageal echo (TEE). However, 4D. ICE usage continues to grow in both standalone and concomitant procedures. Siemens Healthineers’ ICE system uses a catheter with an ultrasound probe to create real-time, 3D moving images. It shows the heart’s. dynamic motion and blood flow. The 4D element refers to the three spatial dimensions, plus the dimension of time, which provides a live video feed of the heart.
Boston Scientific says the partnership can support the growth of its Watchman business. It could enable an improved workflow that can expand procedural adoption across more sites while reducing barriers for patients and driving operational efficiency.
The announcement comes one day after Siemens announced plans to deconsolidate Siemens Healthineers in a spin-off.
